Tenet healthcare director J. Robert Kerrey sells $1.19 million in stock

J. Robert Kerrey, a director at Tenet Healthcare Corp (NYSE:THC), has sold a significant portion of his holdings in the company. According to a recent SEC filing, Kerrey sold a total of 9,525 shares of Tenet Healthcare common stock on March 11, 2025. The shares were sold at prices ranging from $124.6 to $126.8 per share, resulting in a total transaction value of approximately $1.19 million. This sale comes as the company, currently valued at $11.57 billion, trades at an attractive P/E ratio of 3.69. InvestingPro data shows analyst price targets ranging from $134 to $217, suggesting potential upside.

Following these transactions, Kerrey’s direct holdings in the company decreased to 27,378 shares. Tenet Healthcare, based in Dallas, Texas, operates a network of healthcare facilities and is publicly traded on the New York Stock Exchange under the ticker THC. The company maintains a "GREAT" financial health score according to InvestingPro, which offers 8 additional key insights about THC’s performance and outlook in its comprehensive Pro Research Report.

In other recent news, Tenet Healthcare’s financial performance and strategic initiatives have been the focus of several analyst reports. The company reported fourth-quarter 2024 results that slightly exceeded expectations, with adjusted EBITDA of $793 million and adjusted earnings per share of $3.44, surpassing consensus estimates. Analysts at Raymond (NSE:RYMD) James noted the company’s strong performance in its Ambulatory Surgery Center segment, which outperformed their estimates. Despite these positive results, Tenet’s stock has faced challenges, partly due to broader market concerns about potential policy changes affecting the healthcare sector.

Truist Securities reiterated a Buy rating for Tenet Healthcare, citing solid demand trends and strategic moves to reduce debt and enhance financial flexibility. Similarly, TD Cowen initiated coverage with a Buy rating, highlighting Tenet’s efforts to reshape its business structure and reduce debt. Cantor Fitzgerald maintained an Overweight rating, acknowledging challenges but expressing confidence in Tenet’s conservative strategy and long-term value.

Raymond James adjusted its price target for Tenet Healthcare to $185, emphasizing the company’s strong secular drivers and improved balance sheet. KeyBanc also maintained an Overweight rating with a $185 price target, noting Tenet’s solid fourth-quarter results and ongoing debt reduction. Analysts from KeyBanc remain optimistic about the company’s long-term prospects, particularly its United Surgical Partners International business, despite current market uncertainties.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.